Site-central discordance in oncology trial imaging: New benchmarks and management strategies

When site investigators and blinded independent central reviewers (BICR) both assess treatment response in an oncology trial participant, sometimes they disagree. How much disagreement should a sponsor expect, and when should they start digging for possible data quality issues? Until now, there has not been much benchmark data to help sponsors decide.

Newly published research has established empirical benchmarks across multiple solid tumor types, providing a more evidence-based framework for interpreting site-BICR discordance during trial conduct. Join Dr. Gregory Goldmacher, Chief Scientific & Medical Officer at Perceptive Imaging, for a discussion of what drives discordance, how it is affected by cancer type and trial design, and what it can mean for clinical trial oversight.

In this webinar, attendees will:

• Examine the factors that drive site-central discordance
• Learn how new empirical benchmarks can put observed discordance into context
• Discuss practical medical monitoring strategies for identifying, evaluating, and responding to discordance during oncology trials